Results 91 to 100 of about 9,247 (168)

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, Volume 66, Issue 8, Page 1679-1685, August 2026.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

British Journal of Haematology, Volume 209, Issue 2, Page 778-781, August 2026.
Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid   +2 more
wiley   +1 more source

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

eJHaem
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy.
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema   +5 more
doaj   +1 more source

Refractory autoimmune hemolytic anemia with poor erythropoietic compensation in combined immunodeficiency: A case series

Pediatric Allergy and Immunology, Volume 37, Issue 8, August 2026.
Letizia Baldini, Mattia Moratti, Alessandro Ruggi, Francesco Licciardi, Fraia Melchionda, Maura Fois, Maria Elena Cantarini, Elena Facchini, Veronica Barat, Giovanni Del Borrello, Bruno Fattizzo, Elena Sabattini, Clara Bertuzzi, Riccardo Masetti, Francesca Conti   +14 more
wiley   +1 more source

Daratumumab as rescue therapy in refractory recurrent FSGS after kidney transplantation: a case series. [PDF]

Transpl Int
Avaniadi PD, Akifova A, Schrezenmeier EV, Lüdemann S, Eleftheriadis G, Güneytepe AS, Gao L, Bachmann F, Hengel FE, Mühlig A, Tomas NM, Huber TB, Eckardt KU, Budde K, Halleck F.   +14 more
europepmc   +1 more source

Defining the biological boundaries of daratumumab monotherapy: long-term insights from the CENTAURUS trial in high-risk smoldering multiple myeloma. [PDF]

Transl Cancer Res
Miura K.
europepmc   +1 more source

Safety and Effectiveness of Daratumumab in Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplant. [PDF]

Kidney Med
Mehta RV, Evans KB, Shah CV, Shukla A, Belal A, Ibrahim H, Alquadan K, Leghrouz M, Vrakas G, Mehta R, Santos A.   +10 more
europepmc   +1 more source

Management of relapsed/refractory AL amyloidosis. [PDF]

Blood Adv
Ling J, Sidiqi MH, Gertz M.
europepmc   +1 more source

Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated Disorders. [PDF]

Cancer Rep (Hoboken)
Roberts K, Valiño Ramos P, Jindal S, Prasad V, Lee YS, Khanfar M, Griffith OL, Griffith M, Jiang J, Cesarman E, Rauch D, Simonson P, Odeny T, Ratner L.   +13 more
europepmc   +1 more source

Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma. [PDF]

Hematol Rep
Rosenberg T, Kirkegaard J, Gundesen MT, Ølholm AM, Dieperink KB, Lund T.   +5 more
europepmc   +1 more source